Assessing hypotension incidence and dosing strategies of sacubitril/valsartan in real-world heart failure management: protocol for a retrospective, multicentre and cohort study


  • Uday M. Jadhav Department of Cardiology and Cardiac CT, MGM New Bombay Hospital, Mumbai, Maharashtra, India
  • Jay Shah Department of Interventional Cardiology and Angiology, Krish Heart Care, Ahmedabad, Gujarat, India
  • Arun Mohanty Department of Intra Vascular Imaging, Sir Ganga Ram Hospital, New Delhi, Delhi, India
  • M. Chenniappan Department of Cardiology, Ramakrishna Medical Centre LLP (Heart Care Unit) Trichy, Tamil Nadu, India
  • Ameet G. Sattur Department of Interventional Cardiology, Sattur Heart Care, Hubli, Karnataka, India
  • Mainak Mukhopadhyay Department of Interventional Cardiology, Amri Hospital, Salt Lake, Kolkata, West Bengal, India
  • K. Naveen Krishna Department of Interventional Cardiology, Aditya Health Clinics, Hyderabad, Telangana, India
  • Madhusudan Raikar Department of Interventional Cardiology, Aster CMI Hospital, Bengaluru, Karnataka, India
  • Suchit B. Mahale Department of Interventional Cardiology, Sanjivini Hospital, Virar, Mumbai, Maharashtra, India
  • Debdatta Majumdar Department of Interventional Cardiology, R.N. Tagore Hospital, Kolkata, West Bengal, India
  • Susanta Shaila Department of Interventional Cardiology, Kalinga Hospital, Bhubaneswar, Odisha, India
  • Gyan Prakash Department of Cardiology, Apollo Spectra Hospital, Patna, Bihar, India
  • Iranna S. Hirapur Department of Cardiology, Gulbarga Heart Foundation, Kalaburagi, Karnataka, India
  • Nasar Abdali Department of Cardiology, Mahavir Vatsalya, Patna, Bihar, India
  • Harish Surwade Department of Interventional Cardiology, Platinum Hospital, Mumbai, Maharashtra, India
  • M. Talha Khan Abid Department of Interventional Cardiology, Fairmed Clinic, Meerut, Uttar Pradesh, India
  • Vikas Thakran Department of Interventional Cardiology, BLK Max Heart Centre, Delhi, India
  • Alok Sharma Department of Interventional Cardiology, Cardiac Unit, MLBMC, Jhansi, Uttar Pradesh, India
  • Nipun Mahajan Department of Interventional Cardiology, Tagore Hospital and Heart Centre, Jalandhar, Punjab, India



Sacubitril/valsartan, Heart Failure, Reduced ejection fraction, Real-world evidence, Blood pressure, Tolerability, Effectiveness


Background: The burden of heart failure (HF) and hypertension in India underscores the need for effective management strategies. Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNi), has emerged as a pivotal therapy for HF with reduced ejection fraction (HFrEF). However, concerns about hypotension often hinder optimal dosing in clinical practice. The primary objective of this study is to observe the incidence of hypotension in HFrEF patients and to evaluate the best clinical practice to achieve an optimal tolerated dose of sacubitril/valsartan without treatment discontinuation. Secondary objectives include evaluating treatment outcomes, tolerability, and factors influencing dosing adjustments.

Methods: This is the protocol of a retrospective, multicentre cohort study aimed at assessing real-world usage patterns of sacubitril/valsartan among Indian HFrEF patients. Patients aged 18-80 years diagnosed with HFrEF (left ventricular ejection fraction (LVEF) ≤40%) and initiated on sacubitril/valsartan between November 2023 and May 2024 will be included. Baseline and follow-up data, including demographics, medical history, and treatment outcomes, will be analysed using appropriate statistical tests. Data from approximately 150 healthcare facilities will be collected using a structured case report form (CRF).

Results: The study was initiated in February 2024. As of manuscript submission, 1039 individuals have been enrolled on the study. Data collection is expected to continue until the end of June 2024.

Conclusions: This study aims to contribute valuable insights into optimizing sacubitril/valsartan therapy for HFrEF patients in India, addressing concerns about hypotension and dosage optimization. The study seeks to inform clinical practice and enhance patient care by elucidating real-world usage patterns and outcomes.


Huffman MD, Prabhakaran D. Heart failure: Epidemiology and prevention in India. Natl Med J India 2010;23(5):283-8.

Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, et al. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail. 2015;17(8):794-800.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032.

McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004.

Pereira SC, Rodrigues T, Nunes-Ferreira A, Agostinho JR, Pinto FJ, Brito D. Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience. J Clin Med. 2023;12(4):1334.

Niu C, Yang S, Ou S, Wu C, Huang P, Hung C, et al. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease. J Am Heart Assoc. 2022;11(18):e026407.

Hsiao FC, Lin CP, Yu CC, Tung YC, Chu PH. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study. Front Cardiovasc Med. 2022;9:794707.

Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372-80.

Dalal J, Chandra P, Ray S, Hazra PK, Hiremath J, Kumar V, et al. Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists. Cardiol Ther. 2023;12(3):445-71.

Kim H, Oh J, Lee S, Ha J, Yoon M, Chun K Hyeon, et al. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Sci Rep. 2021;11:16335.

Park JJ, Lee SE, Cho HJ, Choi JO, Yoo BS, Kang SM, et al. Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study. Int J Heart Fail. 2022;4(4):193-204.

Classes and Stages of Heart Failure. Available at: Accessed on 08 March 2024.

Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, et al. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021;10(4):e019238.